URGN (UroGen Pharma) Days Payable : 304.42 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma Days Payable?

UroGen Pharma's average Accounts Payable for the three months ended in Dec. 2024 was $8.24 Mil. UroGen Pharma's Cost of Goods Sold for the three months ended in Dec. 2024 was $2.47 Mil. Hence, UroGen Pharma's Days Payable for the three months ended in Dec. 2024 was 304.42.

The historical rank and industry rank for UroGen Pharma's Days Payable or its related term are showing as below:

URGN' s Days Payable Range Over the Past 10 Years
Min: 234.75 Med: 539.14 Max: 23516.43
Current: 308.88

During the past 10 years, UroGen Pharma's highest Days Payable was 23516.43. The lowest was 234.75. And the median was 539.14.

URGN's Days Payable is ranked better than
70.96% of 706 companies
in the Biotechnology industry
Industry Median: 123.485 vs URGN: 308.88

UroGen Pharma's Days Payable increased from Dec. 2023 (210.66) to Dec. 2024 (304.42). It may suggest that UroGen Pharma delayed paying its suppliers.

UroGen Pharma Days Payable Historical Data

The historical data trend for UroGen Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Days Payable Chart

UroGen Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

1,440.65

320.52

269.74

234.75

358.49

UroGen Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															210.66	337.25	298.35	258.03	304.42

Competitive Comparison of UroGen Pharma's Days Payable

For the Biotechnology subindustry, UroGen Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Days Payable falls into.

Save Embed

;

Save Embed

;

UroGen Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

UroGen Pharma's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (6.514	+	10.931)	/	2 )	/	8.881	*	365
=	8.7225					/	8.881	*	365
=	358.49

UroGen Pharma's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (5.556	+	10.931)	/	2 )	/	2.471	*	365 / 4
=	8.2435					/	2.471	*	365 / 4
=	304.42

UroGen Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

0XOD:UK UR8:Germany

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Executives

Mark Schoenberg	officer: Chief Medical Officer	C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Jason Drew Smith	officer: General Counsel	C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Daniel George Wildman	director	12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen	director	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim	officer: Chief Financial Officer	C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett	officer: Chief Executive Officer	C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix	officer: COO	C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden	director	C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur	director, officer: Chief Executive Officer	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen	director	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102